Microencapsulation of PEGylated Adenovirus within PLGA Microspheres for Enhanced Stability and Gene Transfection Efficiency
暂无分享,去创建一个
Tae Gwan Park | T. Park | Hyejung Mok | Hyejung Mok | Ji Won Park | Ji Park
[1] T. Park,et al. Pegylation enhances protein stability during encapsulation in PLGA microspheres. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[2] T. Park,et al. Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres , 1993, Pharmaceutical Research.
[3] D. Majhen,et al. Adenoviral vectors--how to use them in cancer gene therapy? , 2006, Virus research.
[4] J. Hennessey,et al. Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption. , 2002, Virology.
[5] Tae Gwan Park,et al. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. , 2002, Biomaterials.
[6] D. Muruve,et al. The innate immune response to adenovirus vectors. , 2004, Human gene therapy.
[7] L. Medina-Kauwe. Endocytosis of adenovirus and adenovirus capsid proteins. , 2003, Advanced drug delivery reviews.
[8] M. Barry,et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Davidson,et al. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. , 1997, Advanced drug delivery reviews.
[10] Xuan Cheng,et al. PEGylated Adenoviruses for Gene Delivery to the Intestinal Epithelium by the Oral Route , 2003, Pharmaceutical Research.
[11] M. Mizuno,et al. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models , 2002, Cancer Gene Therapy.
[12] T. Park,et al. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[13] D. Lewis,et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[14] B. Trapnell,et al. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.
[15] H. Merkle,et al. Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[16] H. Mizuguchi,et al. Targeted adenovirus vectors. , 2004, Human gene therapy.
[17] C Russell Middaugh,et al. Effect of pH and ionic strength on the physical stability of adenovirus type 5. , 2006, Journal of pharmaceutical sciences.
[18] J. Wilson,et al. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.
[19] M. Herlyn,et al. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] M. Rots,et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. , 2004, Human gene therapy.
[21] Alan E. Smith,et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.
[22] G. Kwon,et al. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[23] T. Park,et al. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. , 2006, Bioconjugate chemistry.
[24] M. Burton,et al. In-vitro evaluation of ion-exchange microspheres for the sustained release of liposomal-adenoviral conjugates. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[25] J. Wilson,et al. Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] Chung C. Hsu,et al. Effect of high shear on proteins , 2000, Biotechnology and bioengineering.
[27] B. Davidson,et al. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo , 1998, Gene Therapy.
[28] T. Burke,et al. The Acidic Microclimate in Poly(lactide-co-glycolide) Microspheres Stabilizes Camptothecins , 1999, Pharmaceutical Research.
[29] M. Mccaman,et al. Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye. , 1999, Analytical biochemistry.
[30] M. Burton,et al. A Microsphere-Liposome (Microplex) Vector for Targeted Gene Therapy of Cancer. II. In Vivo Biodistribution Study in a Solid Tumor Model , 2000, Drug delivery.
[31] Alberto Smith,et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. , 2005, Angewandte Chemie.
[32] F. Mi,et al. Chitin/PLGA blend microspheres as a biodegradable drug delivery system: a new delivery system for protein. , 2003, Biomaterials.
[33] J. Maizel,et al. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.